Zezheng Shanghai Biotechnology Co Ltd.

The main purpose of the study is to use the lidocaine prilocaine aerosol (trade name: Fortacin) licensed by Recordati Ireland Ltd as the reference preparation and the lidocaine prilocaine aerosol developed by Zezheng (Shanghai) Biotechnology Co., Ltd. as the test preparation to evaluate the safety and tolerability of the reference preparation and the test preparation in single and continuous administration in healthy Chinese male subjects. Secondary purpose of the study: To evaluate the pharmacokinetic (PK) characteristics of the reference preparation and the test preparation in single and continuous administration in healthy Chinese male subjects.

The main purpose of the study is to use the lidocaine prilocaine aerosol (trade name: Fortacin) licensed by Recordati Ireland Ltd as the reference preparation and the lidocaine prilocaine aerosol developed by Zezheng (Shanghai) Biotechnology Co., Ltd. as the test preparation to evaluate the safety and tolerability of the reference preparation and the test preparation in single and continuous administration in healthy Chinese female subjects. Secondary purpose of the study: To evaluate the pharmacokinetic (PK) characteristics of the reference preparation and the test preparation in single and continuous administration in healthy Chinese female subjects.

The main purpose of the study is to use Sanofi/Aventis.'s licensed amisulpride tablets (200 mg) as the control preparation and HQ-0124 tablets (200 mg) developed by Zezheng (Shanghai) Biotechnology Co., Ltd. as the test preparation, and to evaluate the bioequivalence of the two preparations in the fasting and postprandial state through a single-center, randomized, open, single-dose, two-cycle, double-crossover clinical study. Secondary purpose of the study: To observe the safety of the test preparation and the control preparation in healthy Chinese subjects.